Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action.

Pasut, G., Greco, F., Mero, A., Mendichi, R., Fante, C., Green, R. J. and Veronese, F. (2009) Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. Journal of Medicinal Chemistry, 52 (20). pp. 6499-6502. ISSN 0022-2623 doi: 10.1021/jm900804m

Abstract/Summary

We developed a family of polymer-drug conjugates carrying the combination of the anticancer agent epirubicin (EPI) and nitric oxide (NO). EPI-PEG-(NO)8, carrying the highest content of NO, displayed greater activity in Caco-2 cells while it decreased toxicity against endothelium cells and cardiomyocytes with respect to free EPI. FACS and confocal microscopy confirmed conjugates internalization. Light scattering showed formation of micelle whose size correlated with internalization rate. EPI-PEG-(NO)8 showed increased bioavailability in mice compared to free EPI.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/4408
Item Type	Article
Refereed	Yes
Divisions	Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Pharmaceutics Research Group
Uncontrolled Keywords	pegylated epirubicin; breast-cancer; chemotherapy; cytotoxicity; release
Publisher	American Chemical Society
Download/View statistics	View download statistics for this item